Highlights of weekly biotech stock moves

Gilead Sciences Inc. (NASDAQ:GILD) lost $0.40 to $38.39 last week after resubmitting an NDA to FDA for a fixed-dose combination of rilpivirine and Truvada emtricitabine/tenofovir to treat HIV infection. Last month, the agency refused to file the application and requested additional information on the analytical methodology and qualification data used to establish acceptable levels of recently identified degradants related to emtricitabine.

Gilead and Johnson & Johnson (NYSE:JNJ) are developing the combination of J&J's rilpivirine and Gilead's Truvada...